Erratum (DOI:10.1016/S1470-2045(08)70261-4);Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study

The Lancet Oncology

Volumn 9, Issue 12, 2008, Pages 1135-1142

  Kubota, Kaoru ^a   Kawahara, Masaaki ^b   Ogawara, Mitsumasa ^b   Nishiwaki, Yutaka ^a   Komuta, Kiyoshi ^c   Minato, Koichi ^d   Fujita, Yuka ^e   Teramukai, Satoshi ^f   Fukushima, Masanori ^f   Furuse, Kiyoyuki ^g  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d GUNMA PREFECTURAL CANCER CENTER   (Japan)

^e Dohoku National Hospital   (Japan)

^f KYOTO UNIVERSITY HOSPITAL   (Japan)

^g Japan Multinational Trial O   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CIMETIDINE; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GEFITINIB; GEMCITABINE; LACTATE DEHYDROGENASE; NAVELBINE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 56449124059     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70324-3     Document Type: Erratum

References (38)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
3. Schiller J.H., Harrington D., Belani C.P., et al. Comparison or four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Ohe Y., Ohashi Y., Kubota K., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18 (2006) 317-323
5. Georgoulias V., Ardavanis A., Tsiafaki X., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23 (2005) 2937-2945
6. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357 (2001) 1478-1484
7. Isokangas O.P., Knuuttila A., Halme M., et al. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 10 (1999) 1059-1063
8. Gridelli C., Frontini L., Perrone F., et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Br J Cancer 83 (2000) 707-714
9. Tan E.H., Szczesna A., Krzakowski M., et al. Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49 (2005) 233-240
10. Roszkowski K., Pluzanska A., Krzakowski M., et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27 (2000) 145-157
11. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
12. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 (2000) 2354-2362
13. Hosoe S., Komuta K., Shibata K., et al. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer 88 (2003) 342-347
14. Williamson S.K., Crowley J.J., Lara Jr. P.N., et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23 (2005) 9097-9104
15. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
16. National Cancer Institute. Common Toxicity Criteria version 2.0. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf (accessed Oct 22, 2008).
17. Ogawara M., Kawahara M., Hosoe S., et al. A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC=6 in untreated advanced non-small cell lung cancer patients in Japan. Jpn J Clin Oncol 32 (2002) 48-53
18. Crowley J., and Breslow N. Statistical analysis of survival data. Annu Rev Public Health 5 (1984) 385-411
19. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
20. Cox D.R. Regression models and life tables. J R Stat Soc Ser B 34 (1972) 187-220
21. Tada H., Matsui S., Kawahara M., Hosoe S., Hamada C., and Fukushima M. Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience. Eur J Cancer Care 17 (2008) 120-126
22. Yamamoto N., Nakagawa K., Uejima H., et al. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced non small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107 (2006) 599-605
23. Inoue A., Saijo Y., Maemondo M., et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361 (2003) 137-139
24. Niho S., Kubota K., Goto K., et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 24 (2006) 64-69
25. Edelman M.J., Clark J.I., Chansky K., et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10 (2004) 5022-5026
26. Fidias P., Dakhil S., Lyss A., et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: updated report with survival. J Clin Oncol 25 suppl (2007) 18S:LBA7516.
27. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
28. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008) 3543-3551
29. Ciuleanu T.E., Brodowicz T., Belani C.P., et al. Maintenance pemetrexed plus best supportive care (BSC): a phase III study. Proc Am Soc Clin Oncol 26 suppl (2008) 8011
30. Hida T., Okamoto I., Kashii T., et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). J Clin Oncol 26 suppl (2008) LBA8012.
31. Teramukai S., Nishimura T., Nakagawa M., et al. Predictors and impacts of second-line chemotherapy on survival after progression in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 25 suppl (2007) 18S:7675.
32. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
33. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353 (2005) 123-132
34. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
35. Sekine I., Nokihara H., Yamamoto N., et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 53 (2006) 157-164
36. Ando Y., Minami H., Saka H., et al. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 76 (1997) 1067-1071
37. Myers G.L., Miller W.G., Coresh J., et al. Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the national kidney disease education program. Clin Chem 52 (2006) 5-18
38. Ando M., Minami H., Ando Y., et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 6 (2000) 4733-4738